Earnings Call Summary | Monogram Orthopaedics(MGRM.US) Q1 2024 Earnings Conference
Earnings Call Summary | Monogram Orthopaedics(MGRM.US) Q1 2024 Earnings Conference
The following is a summary of the Monogram Technologies Inc. (MGRM) Q1 2024 Earnings Call Transcript:
以下是Monogram Technologries Inc.（MGRM）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Monogram Technologies Inc. ended Q1 2024 with a cash balance of $10.1 million.
The company paid down the accounts payable balance by a net total of $1.1 million.
60% of Monogram Technologies Inc's expenses are attributed to labor costs.
The company holds no debt or warrant obligations, presaging adequate access to cash for future operations.
截至2024年第一季度，Monogram Technologries Inc.的現金餘額爲1,010萬美元。
該公司淨付了110萬美元的應付賬款餘額。
Monogram Technologries Inc的60％支出歸因於勞動力成本。
該公司沒有債務或認股權證債務，這預示着未來運營有足夠的現金可用。
Business Progress:
業務進展：
Nine out of fifteen simulations of end-to-end surgeries on cadaveric specimens were successful.
Developments have been made on the mVision navigation, Monogram's AI-enabled system.
Monogram Technologies received positive feedback from FDA on its verification and validation testing plans.
The company has begun an aggressive resourcing strategy and plans to submit its product for 510(k) approval.
It aims to enter the robotics market in joint replacements, challenging incumbent Stryker's Mako.
Monogram Technologies plans to submit the 510(k) application for FDA clearance with most of its testing expected to be complete by the end of this quarter.
The company's 'one robot for the operating room' business model leveraging its autonomous cutting system is under development.
The robot for knee surgeries is undergoing IEC 60601 standards certification.
Monogram expects to conduct first live surgeries using their robot post FDA clearance, and integration plans of mVision into their robotic pipeline are in progress.
The company is also exploring more investment opportunities through a small bridge.
在對屍體標本進行端到端手術的十五次模擬中，有九次是成功的。
Monogram的人工智能系統mVision導航已經取得了進展。
Monogram Technologrys收到了美國食品和藥物管理局對其驗證和驗證測試計劃的積極反饋。
該公司已經開始了積極的資源配置戰略，並計劃將其產品提交510（k）批准。
它的目標是通過關節替代品進入機器人市場，挑戰現任Stryker的Mako。
Monogram Technologrys計劃提交510（k）份申請以獲得美國食品藥品管理局的批准，其大部分測試預計將在本季度末之前完成。
該公司利用其自主切割系統的 “一臺手術室機器人” 商業模式正在開發中。
用於膝關節手術的機器人正在接受IEC 60601標準認證。
Monogram預計將在獲得美國食品藥品管理局批准後使用其機器人進行首次活體手術，並將mVision整合到其機器人管道的計劃正在進行中。
該公司還在通過一座小橋探索更多的投資機會。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。